-
Mashup Score: 1
New draft guidance discusses the data necessary for deciding whether an effect on a surrogate or intermediate clinical endpoint is reasonably like to predict clinical benefit and can support accelerated approval.
Source: insights.citeline.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 0Boston Scientific’s Head Of Urology Says Axonics Acquisition ‘Brings A More Comprehensive Gender Balance’ - 29 day(s) ago
Medtech Insight spoke with Meghan Scanlon, president of Boston Scientific’s urology division, about integration plans for the recently acquired Axonics medtech. The purchase adds sacral neuromodulation to Boston Scientific’s portfolio, a global market that research reports valued at $1.6bn in 2023.
Source: insights.citeline.comCategories: General Medicine News, General HCPsTweet-
.@BostonSci Head Of #Urology Says Axonics Acquisition ‘Brings A More Comprehensive Gender Balance’ | #MnA #medicaldevices https://t.co/MLAZf715HF
-
-
Mashup Score: 2Robert F. Kennedy Jr. As HHS Secretary: Prepare For The Worst, But Hope For The Best - 1 month(s) ago
Kennedy’s nomination for HHS secretary already is drawing concerns, which could mean a more conventional pick emerges, but industry should prepare for Kennedy to control the US Health and Human Services Department for at least some time.
Source: insights.citeline.comCategories: General Medicine News, Rare DiseaseTweet-
RT @PharmaPinkSheet: Robert F. Kennedy Jr. As HHS Secretary: Prepare For The Worst, But Hope For The Best https://t.co/k74r9C5SHR #PinkShee…
-
-
Mashup Score: 2Genetic Testing Company 23andMe Cuts 40% Of Workforce, Discontinues Drug Development Business - 1 month(s) ago
23andMe cut 40% of its workforce and will discontinue its therapeutic program as part of ongoing restructuring. This comes after a data breach, series of layoffs and the resignation of its board members.
Source: insights.citeline.comCategories: General Medicine News, General HCPsTweet-
RT @medtechMarion: Genetic Testing Company 23andMe Cuts 40% Of Workforce, Discontinues Drug Development Business https://t.co/8VsDdxaD8P @C…
-
-
Mashup Score: 1SVB Report Finds 2024 Resurgence In Healthtech Investment, Driven Largely By Investments In AI - 2 month(s) ago
Venture capital investment in healthtech is showing signs of early recovery in the first half of 2024 after the long hangover of a downturn that followed booming investments during the pandemic years, according to a new report from Silicon Valley Bank (SVB). Despite ongoing challenges, healthtech is on a positive trajectory and hovers between $3.5bn and $4.5bn per quarter, surpassing pre-pandemic levels.
Source: insights.citeline.comCategories: General Medicine News, General HCPsTweet-
RT @medtechMarion: SVB Report Finds 2024 Resurgence In Healthtech Investment, Driven Largely By Investments In AI https://t.co/5QQDqO5UaB #…
-
RT @PharmaPinkSheet: Accelerated Approval: US FDA Explains ‘Reasonably Likely’ Determination Criteria https://t.co/OXDOouwqxc #PinkSheet ht…